(Q46018739)

English

Efficacy and safety of casopitant mesylate, a neurokinin 1 (NK1)-receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy: a randomised, double-blind, placebo

scientific article published on 8 May 2009

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19428297

Efficacy and safety of casopitant mesylate, a neurokinin 1 (NK1)-receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy: a randomised, double-blind, placebo (English)

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19428297

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

2

object named as

Janusz Rolski

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19428297

author name string

Steven M Grunberg

1

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19428297

Janos Strausz

3

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19428297

Zeba Aziz

4

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19428297

Stephen Lane

5

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19428297

Mark W Russo

6

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19428297

Paul Wissel

7

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19428297

Mary Guckert

8

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19428297

Oliver Wright

9

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19428297

Jørn Herrstedt

10

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19428297

publication date

8 May 2009

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19428297

Lancet Oncology Commission

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19428297

10

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19428297

6

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19428297

549-558

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19428297

Serotonin antagonists: a new class of antiemetic agents

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970109-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970109-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Ondansetron compared with granisetron in the prophylaxis of cyclophosphamide-induced emesis in out-patients: a multicentre, double-blind, double-dummy, randomised, parallel-group study. Emesis Study Group for Ondansetron and Granisetron in Breast Ca

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970109-3

7 January 2021

based on heuristic

inferred from DOI database lookup

The role of the 5-HT3 antagonists ondansetron and dolasetron in the control of delayed onset nausea and vomiting in patients receiving moderately emetogenic chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970109-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Chemotherapy-Induced Nausea and Vomiting

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970109-3

7 January 2021

based on heuristic

inferred from DOI database lookup

The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 St

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970109-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970109-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Impact of casopitant, a novel NK-1 antagonist, on the pharmacokinetics of ondansetron and dexamethasone

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970109-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Quality of life consequences of chemotherapy-induced emesis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970109-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Assessing the impact of chemotherapy-induced nausea and vomiting on patients' daily lives: a modified version of the Functional Living Index-Emesis (FLIE) with 5-day recall

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970109-3

7 January 2021

based on heuristic

inferred from DOI database lookup

The resurgence of platinum-based cancer chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970109-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Proposal for classifying the acute emetogenicity of cancer chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970109-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970109-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970109-3

7 January 2021

based on heuristic

inferred from DOI database lookup

American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970109-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970109-3

7 January 2021

based on heuristic

inferred from DOI database lookup

One third of patients with radiotherapy-induced nausea consider their antiemetic treatment insufficient.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970109-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970109-3

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier oncology group study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970109-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(09)70109-3

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19428297

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19428297

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46018739&oldid=2134050664"